Arcadia Investment Management Corp MI grew its position in shares of Medidata Solutions Inc (NASDAQ:MDSO) by 35.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 63,803 shares of the company’s stock after purchasing an additional 16,798 shares during the quarter. Arcadia Investment Management Corp MI owned about 0.11% of Medidata Solutions worth $4,043,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Summit Creek Advisors LLC bought a new position in Medidata Solutions during the 4th quarter worth approximately $5,137,000. AMP Capital Investors Ltd bought a new stake in shares of Medidata Solutions in the 3rd quarter valued at $2,194,000. KAMES CAPITAL plc increased its stake in shares of Medidata Solutions by 54.6% in the 4th quarter. KAMES CAPITAL plc now owns 25,521 shares of the company’s stock valued at $1,617,000 after acquiring an additional 9,012 shares in the last quarter. Zions Bancorporation bought a new stake in shares of Medidata Solutions in the 3rd quarter valued at $256,000. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Medidata Solutions by 38.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 326,950 shares of the company’s stock valued at $25,522,000 after acquiring an additional 90,572 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.
In other news, CFO Rouven Bergmann sold 2,000 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $65.40, for a total transaction of $130,800.00. Following the completion of the transaction, the chief financial officer now owns 91,775 shares of the company’s stock, valued at $6,002,085. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carlos Dominguez sold 9,066 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $66.85, for a total value of $606,062.10. Following the transaction, the director now directly owns 66,020 shares of the company’s stock, valued at approximately $4,413,437. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,010 shares of company stock worth $1,630,556. Company insiders own 5.80% of the company’s stock.
Shares of Medidata Solutions Inc (NASDAQ MDSO) remained flat at $$62.48 during trading on Wednesday. 806,300 shares of the stock were exchanged, compared to its average volume of 635,044. Medidata Solutions Inc has a 1 year low of $54.36 and a 1 year high of $85.92. The firm has a market capitalization of $3,661.76, a P/E ratio of 71.82, a PEG ratio of 3.07 and a beta of 1.58. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.37 and a current ratio of 1.50.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.10. Medidata Solutions had a return on equity of 11.59% and a net margin of 8.14%. The firm had revenue of $141.20 million for the quarter, compared to analysts’ expectations of $140.65 million. During the same period in the prior year, the business posted $0.33 earnings per share. The company’s revenue was up 13.4% on a year-over-year basis. sell-side analysts expect that Medidata Solutions Inc will post 1 EPS for the current year.
MDSO has been the subject of several research analyst reports. TheStreet lowered shares of Medidata Solutions from a “b” rating to a “c+” rating in a research note on Thursday, December 14th. Zacks Investment Research downgraded shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Wells Fargo & Co reduced their price target on shares of Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a research report on Friday, October 27th. SunTrust Banks reaffirmed a “buy” rating and set a $92.00 price objective on shares of Medidata Solutions in a report on Friday, October 27th. Finally, Deutsche Bank began coverage on shares of Medidata Solutions in a report on Friday, December 8th. They set a “buy” rating and a $78.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Medidata Solutions presently has a consensus rating of “Buy” and an average price target of $82.07.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/14/medidata-solutions-inc-mdso-stake-increased-by-arcadia-investment-management-corp-mi.html.
Medidata Solutions Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.